Evidence map›Paper›PMID 40055122›Full record

ArticleInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2025

Effect of substantial lymphovascular space invasion on location of first disease recurrence in surgical stage I endometrioid endometrial adenocarcinoma.

Christian Dagher, Pernille Bjerre Trent, Rofieda Alwaqfi, Ben Davidson, Lora H Ellenson, Qin Zhou, Alexia Iasonos, Jennifer J Mueller, Kaled Alektiar, Vicky Makker and 7 more

Erratum issuedAbstract readMulticenter Study
In one paragraph

Article in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Christian DagherMemorial Sloan Kettering Cancer Center, Department of Surgery, Gynecology Service, New York, NY, USA.
Pernille Bjerre TrentNorwegian Radium Hospital, Oslo University Hospital, Department of Surgical Oncology, Section for Gynaecological Oncology, Oslo, Norway; University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway.
Rofieda AlwaqfiMemorial Sloan Kettering Cancer Center, Department of Pathology and Laboratory Medicine, New York, NY, USA.
Ben DavidsonUniversity of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway; Oslo University Hospital, Norwegian Radium Hospital, Department of Pathology, Oslo, Norway.
Lora H EllensonMemorial Sloan Kettering Cancer Center, Department of Pathology and Laboratory Medicine, New York, NY, USA.
Qin ZhouMemorial Sloan Kettering Cancer Center, Department of Epidemiology & Biostatistics, New York, NY, USA.
Alexia IasonosMemorial Sloan Kettering Cancer Center, Department of Epidemiology & Biostatistics, New York, NY, USA.
Jennifer J MuellerMemorial Sloan Kettering Cancer Center, Department of Surgery, Gynecology Service, New York, NY, USA; Weill Cornell Medical College, Department of Obstetrics and Gynecology, New York, NY, USA.
Kaled AlektiarMemorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York, NY, USA.
Vicky MakkerMemorial Sloan Kettering Cancer Center, Department of Medicine, Gynecologic Medical Oncology Service, New York, NY, USA; Weill Cornell Medical College, Department of Medicine, New York, NY, USA.
Jacqueline FeinbergMemorial Sloan Kettering Cancer Center, Department of Surgery, Gynecology Service, New York, NY, USA; Weill Cornell Medical College, Department of Obstetrics and Gynecology, New York, NY, USA.
Evan SmithMemorial Sloan Kettering Cancer Center, Department of Surgery, Gynecology Service, New York, NY, USA; Weill Cornell Medical College, Department of Obstetrics and Gynecology, New York, NY, USA.
Sarah H KimMemorial Sloan Kettering Cancer Center, Department of Surgery, Gynecology Service, New York, NY, USA; Weill Cornell Medical College, Department of Obstetrics and Gynecology, New York, NY, USA.
Sana HatoumMemorial Sloan Kettering Cancer Center, Department of Surgery, Gynecology Service, New York, NY, USA.
Mario M LeitaoMemorial Sloan Kettering Cancer Center, Department of Surgery, Gynecology Service, New York, NY, USA; Weill Cornell Medical College, Department of Obstetrics and Gynecology, New York, NY, USA.
Nadeem R Abu-RustumMemorial Sloan Kettering Cancer Center, Department of Surgery, Gynecology Service, New York, NY, USA; Weill Cornell Medical College, Department of Obstetrics and Gynecology, New York, NY, USA. Electronic address: Abu-rusn@mskcc.org.
Ane Gerda Z ErikssonNorwegian Radium Hospital, Oslo University Hospital, Department of Surgical Oncology, Section for Gynaecological Oncology, Oslo, Norway; University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

objectiveLymphovascular invasion can predict nodal spread and recurrence in endometrioid endometrial cancer; however, the impact of lymphovascular invasion quantification on local versus distant recurrence in surgically staged patients has not yet been established.

methodsThis multicenter, retrospective cohort study included surgically staged patients with International Federation of Obstetrics and Gynecology 2009 stage I node-negative endometrioid endometrial cancer. Patients were treated between January 2012 and December 2019 at 2 tertiary cancer centers. Staging included a total hysterectomy and lymph node assessment. The extent of lymphovascular invasion was defined using the World Health Organization criteria as focal (<5 vessels involved on at least 1 pathology slide) or substantial (≥5 vessels involved). Recurrence and death were considered as events. A competing risk analysis was performed and controlled for multicenter clustering.

resultsOverall, 1555 patients met the inclusion criteria: 65 (4.2%) had substantial invasion, 119 (7.7%) had focal, and 1371 (88.2%) had no invasion. The median follow-up was 61.5 months (range; 0.8-133.9). There were 173 evaluable events among the 1554 patients: 56 local recurrences, 43 distant recurrences, and 74 deaths without recurrence. Deep (>50%) myoinvasion and grade 3 histology were more frequently observed in patients with substantial myoinvasion. Overall, 323 patients (20.8%) received adjuvant therapy. The 5-year cumulative incidence failure rates for any recurrence were 6.0% for no, 19.5% for focal, and 19.0% for substantial invasion. Compared to no lymphovascular invasion, substantial invasion was associated with an increased risk of distant recurrence (adjusted HR 2.29, 95% CI 1.17 to 4.46).

conclusionsIn patients with surgical stage I endometrioid endometrial cancer, the focal and substantial lymphovascular invasion was associated with a 3-fold increased risk of cumulative incidence failure versus no lymphovascular invasion. Patients with substantial invasion had more deeply invasive and grade 3 tumors and appeared to experience more distant than local recurrences. These findings challenge the International Federation of Obstetrics and Gynecology 2023 staging classification that combines no lymphovascular invasion and focal lymphovascular invasion into a single risk category.

Indexed as

Carcinoma, EndometrioidEndometrial NeoplasmsNeoplasm Recurrence, LocalAdultAgedAged, 80 and overFemaleHumansHysterectomyLymphatic MetastasisLymphatic VesselsLymph NodesMiddle AgedNeoplasm InvasivenessNeoplasm StagingRetrospective StudiesEndometrial CancerLymphovascular Space InvasionRecurrence

Identifiers

PMID40055122
PMCPMC12973446

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.